The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation
Open accessAbstract
Background—: Pulmonary vein isolation (PVI) for atrial fibrillation is associated with a transient increased risk of thromboembolic and hemorrhagic events. We hypothesized that dabigatran can be safely used as an alternative to continuous warfarin for the periprocedural anticoagulation in PVI. Methods and Results—: A total of 999 consecutive patients undergoing PVI were included; 376 patients were on dabigatran (150 mg), and 623 patients were on warfarin with therapeutic international normalized ratio. Dabigatran was held 1 to 2 doses before PVI and restarted at the conclusion of the procedure or as soon as patients were transferred to the nursing floor. Propensity score matching was applied to generate a cohort of 344 patients in each group with balanced baseline data. Total hemorrhagic and thromboembolic complications were similar in both groups, before (3.2% versus 3.9%; P =0.59) and after (3.2% versus 4.1%; P =0.53) matching. Major hemorrhage occurred in 1.1% versus 1.6% ( P =0.48) before and 1.2% versus 1.5% ( P =0.74) after matching in the dabigatran versus warfarin group, respectively. A single thromboembolic event occurred in each of the dabigatran and warfarin groups. Despite higher doses of intraprocedural heparin, the mean activated clotting time was significantly lower in patients who held dabigatran for 1 or 2 doses than those on warfarin. Conclusions—: Our study found no evidence to suggest a higher risk of thromboembolic or hemorrhagic complications with use of dabigatran for periprocedural anticoagulation in patients undergoing PVI compared with uninterrupted warfarin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Cappato, R., Calkins, H., Chen, S.-A., Davies, W., Iesaka, Y., Kalman, J., Kim, Y.-H., Klein, G., Natale, A., Packer, D., et al. (2010) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.109.859116 · Cited by 2,852 · cited 2×
“bleeding complications, however, represent rare but serious consequences.(3) Sheaths and catheters in the left atrium (LA),”
BackgroundEffect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Calkins, H., Kuck, K. H., Cappato, R., Brugada, J., Camm, A. J., Chen, S.-A., Crijns, H. J. G., Damiano, R. J., Davies, D. W., DiMarco, J., et al. (2012) · Heart Rhythm · doi:10.1016/j.hrthm.2011.12.016 · Cited by 1,456
Self-citationWazni, O. M., Marrouche, N. F., Martin, D. O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Schweikert, R., Brachmann, J., Gunther, J., et al. (2005) · JAMA · doi:10.1001/jama.293.21.2634 · Cited by 1,121 · cited 1×
“460 Atrial fibrillation (AF) ablation has evolved during the past decade, providing patients with symptomatic AF an alternative to medical therapy.(1,2) Thromboembolic and”
BackgroundEikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081 · cited 1×
“Interestingly, they reported an alarming 31% complication rate in this age group, which is consistent with recent published data suggesting increased risk of major bleeding in patients ≥75 years old with use of dabigatran 150 mg.(17) Thromboembolic complications occurred in 2% of patients on dabigatran and none in the…”
Result
Cited by
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
Self-citationCalkins, H., Hindricks, G., Cappato, R., Kim, Y.-H., Saad, E. B., Aguinaga, L., Akar, J. G., Badhwar, V., Brugada, J., Camm, J., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.05.012 · Cited by 2,755
Self-citationSteffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Verma, A., Cairns, J. A., Mitchell, L. B., Macle, L., Stiell, I. G., Gladstone, D., McMurtry, M. S., Connolly, S., Cox, J. L., Dorian, P., et al. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.08.001 · Cited by 477
Metadata
- Authors
- Bassiouny, M., Saliba, W., Rickard, J., Shao, M., Sey, A., Diab, M., Martin, D. O., Hussein, A., Khoury, M., Abi-Saleh, B., Alam, S., Sengupta, J., Borek, P. P., Baranowski, B., Niebauer, M., Callahan, T., Varma, N., Chung, M., Tchou, P. J., Kanj, M., Dresing, T., Lindsay, B. D., & Wazni, O.
- Venue
- Circulation: Arrhythmia and Electrophysiology
- Published
- 2013-06
- Volume
- 6
- Issue
- 3
- Pages
- 460-466
- ISSN
- 1941-3084 (ISSN-L)
- 1941-3149
- OpenAlex
- W2022219945
- Cited by
- 164
- References
- 6
- FWCI
- 20.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation. https://app.cochat.ai/papers/10.1161/circep.113.000320
- The paper
- Bassiouny, M., Saliba, W., Rickard, J., Shao, M., Sey, A., Diab, M., Martin, D. O., Hussein, A., Khoury, M., Abi-Saleh, B., Alam, S., Sengupta, J., Borek, P. P., Baranowski, B., Niebauer, M., Callahan, T., Varma, N., Chung, M., Tchou, P. J., . . . Wazni, O. (2013). Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology. https://doi.org/10.1161/circep.113.000320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
